Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prostate Cancer
100%
Circulating Tumor Cells
100%
Functional Characterization
100%
Cancer-specific
100%
Microfluidic Device
100%
Immunocapture
44%
Castration-resistant Prostate Cancer
33%
Prostate Cancer Patients
33%
Tumor Tissue
22%
Drug Target Engagement
22%
Patient-derived
22%
Prostate-specific Membrane Antigen
22%
High Sensitivity
11%
Longitudinal Monitoring
11%
Docetaxel
11%
Androgen Receptor
11%
Molecular Characterization
11%
Cancer Metastasis
11%
Drug Action
11%
Clinical Practice
11%
Paclitaxel
11%
Drug Resistance
11%
Metastasis
11%
Commercially Available
11%
Anticancer Therapy
11%
Leukocyte Adhesion
11%
Blood Samples
11%
On chip
11%
Peripheral Blood
11%
Cancer Mortality
11%
Confocal Microscopy
11%
Point mutation
11%
Healthy Donors
11%
CD45
11%
Functional Assay
11%
Microtubule Bundles
11%
Poor Response
11%
Antibody-antigen
11%
3D Geometry
11%
Target Response
11%
TMPRSS2-ERG Fusion
11%
Taxane Chemotherapy
11%
CellSearch
11%
Docetaxel-resistant
11%
Molecular Understanding
11%
Novel Anticancer Agents
11%
C4-2 Cells
11%
Anti-prostate
11%
Biochemistry, Genetics and Molecular Biology
Anticancer
100%
Confocal Microscopy
50%
TMPRSS2
50%
Point Mutation
50%
Antigen Antibody Complex
50%
Drug Activity
50%
Leukocyte Adherence
50%
Androgen Receptor
50%
Drug Resistance
50%
Chimeric Protein
50%
Medicine and Dentistry
Prostate Cancer
100%
Circulating Tumor Cell
100%
Neoplasm
22%
Prostate Specific Membrane Antigen
22%
Docetaxel
22%
Malignant Neoplasm
11%
Leukocyte Adherence
11%
Androgen Receptor
11%
Anticarcinogen
11%
Metastatic Carcinoma
11%
Point Mutation
11%
Cancer Treatment
11%
Antigen Antibody Complex
11%
Microtubule
11%
Drug Activity
11%
Chimeric Protein
11%
Receptor Type Tyrosine Protein Phosphatase C
11%
Paclitaxel
11%
Drug Resistance
11%
Chemotherapy
11%
Confocal Microscopy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Neoplasm
100%
Docetaxel
18%
Prostate Specific Membrane Antigen
18%
Confocal Microscopy
9%
Malignant Neoplasm
9%
Androgen Receptor
9%
Chemotherapy Regimens
9%
Anticarcinogen
9%
Paclitaxel
9%
Chimeric Protein
9%
Receptor Type Tyrosine Protein Phosphatase C
9%
Drug Resistance
9%
Taxane
9%
Immunology and Microbiology
Circulating Tumor Cell
100%
Prostate
33%
Prostate Specific Membrane Antigen
22%
Immune Complex
11%
Drug Resistance
11%
Leukocyte Adherence
11%
Point Mutation
11%
Microtubule
11%
Receptor Type Tyrosine Protein Phosphatase C
11%
Drug Activity
11%
Confocal Microscopy
11%